Followers | 9 |
Posts | 750 |
Boards Moderated | 0 |
Alias Born | 10/19/2008 |
Wednesday, March 05, 2014 12:46:35 PM
While it is legitimate to call NNVC’s actions a distraction of sorts, one must also understand that legal actions are separate, take minimal time from the principal clinical investigators at NNVC, and are required to be done.
These actions are required because if not, others use NNVC inaction as in indication of guilt and/or the hiding of improprieties.
It is a sad aspect of our society that in our legal system, if one does not within a reasonable period of time officially protest being libeled, then that then becomes circumstantial evidence against them that no said libelous action has taken place.
Pump terminator, facilitated through Seeking Alpha’s willing portal and support, also made indication that similar action would continue. NNVC is therefore forced to respond forcefully and officially as a matter of record in a timely manner, pure and simple.
I also agree with the postulate made by an earlier post that this action, as it brings forth more avenues for discovery, shows a confidence by NNVC management of their position and the lack of intent to perform harm with any such questioned past actions.
While unfortunate to be necessary, these actions improve NNVC’s standing.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM